Find Clinical Trial

Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS)


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

Active Substance

S055746

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS055746
Protocol CodeCL1-055746-002
EudraCT Code2014-002559-24
NCT CodeNCT02920541
ISRCTN CodeISRCTN73586707


Documents and links

Lay summary READ MORE
Results summary READ MORE




Quote

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility